We are live on
!
Find out more
DMK
David M. Knott Portfolio holdings
AUM
$275M
Turnover
23.21%
1-Year Est. Return
59.23%
This Fund
S&P 500
This Quarter
Est. Return
+6.72%
1 Year Est. Return
+59.23%
3 Year Est. Return
+80.95%
5 Year Est. Return
+223.18%
10 Year Est. Return
–
AUM
$281M
AUM Growth
+$47.6M
(+20%)
Cap. Flow
+$23.4M
Cap. Flow
% of AUM
8.3%
Top 10 Holdings %
Top 10 Hldgs %
45.9%
Holding
164
New
35
Increased
26
Reduced
12
Closed
17
Avg Time Held Equity + Options
2.4
years
Top 10 Avg Time Held Equity + Options
2
years
Top 20 Avg Time Held Equity + Options
1.7
years
Avg Time Held Equity only
2.4
years
Top 10 Avg Time Held Equity only
2
years
Top 20 Avg Time Held Equity only
1.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coliseum Acquisition Corp. Unit
MITAU
|
+$14.7M |
| 2 |
PSTH
Pershing Square Tontine Holdings, Ltd.
PSTH
|
+$6.6M |
| 3 |
FAZE
FaZe Holdings Inc. Common Stock
FAZE
|
+$5.13M |
| 4 |
Twelve Seas Investment Company II Class A Common Stock
TWLV
|
+$4.99M |
| 5 |
GLHA
Glass Houses Acquisition Corp. Class A common stock
GLHA
|
+$4.83M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 27.9% |
| 2 | Healthcare | 23.27% |
| 3 | Miscellaneous | 14.09% |
| 4 | Materials | 10.3% |
| 5 | Communication Services | 8.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $3M | 1.06% |
32,000
-8,614
| -21% | -$793K |
2018 Q2
12 quarters
|
|
27
Bristol-Myers Squibb
BMY
$122B
| $2.9M | 1.03% |
43,409
-8,000
| -16% | -$522K |
2017 Q1
17 quarters
|
|
|
GLHAW
28
DELISTED
Glass Houses Acquisition Corp. Warrant
GLHAW
| $2.88M | 1.02% |
+250,000
| New | +$220K |
2021 Q2
0 quarters
|
|
29
JPMorgan Chase
JPM
$902B
| $2.83M | 1% |
18,170
+2,700
| +17% | +$424K |
2013 Q2
32 quarters
|
|
30
United Therapeutics
UTHR
$22.9B
| $2.75M | 0.98% |
15,300
+800
| +6% | +$152K |
2021 Q1
1 quarter
|
|
31
Xenon Pharmaceuticals
XENE
$3.24B
| $2.62M | 0.93% |
140,551
-3,550
| -2% | -$65.4K |
2017 Q3
15 quarters
|
|
32
Brightstar Lottery PLC
BRSL
$1.74B
| $2.58M | 0.92% |
107,500
| – | – |
2019 Q1
9 quarters
|
|
|
EIGR
33
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $2.44M | 0.87% |
9,552
+334
| +4% | +$83.4K |
2017 Q3
15 quarters
|
|
34
AllianceBernstein
AB
$3.21B
| $2.35M | 0.84% |
50,500
| – | – |
2013 Q2
32 quarters
|
|
|
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
| $2.15M | 0.77% |
124,688
+7,000
| +6% | +$129K |
2020 Q1
5 quarters
|
|
36
Aurinia Pharmaceuticals
AUPH
$2.2B
| $2.14M | 0.76% |
164,840
+10,000
| +6% | +$127K |
2020 Q1
5 quarters
|
|
|
HZON
37
DELISTED
Horizon Acquisition Corporation II
HZON
| $2.09M | 0.74% |
+210,100
| New | +$2.1M |
2021 Q2
0 quarters
|
|
|
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.05M | 0.73% |
304,922
+32,077
| +12% | +$255K |
2020 Q4
2 quarters
|
|
|
39
DELISTED
Twelve Seas Investment Company II Warrant
TWLVW
| $1.98M | 0.7% |
+171,666
| New | +$125K |
2021 Q2
0 quarters
|
|
40
TG Therapeutics
TGTX
$8.26B
| $1.95M | 0.69% |
50,373
-1,600
| -3% | -$62.8K |
2020 Q2
4 quarters
|
|
41
DELISTED
Priveterra Acquisition Corp. II Class A Common Stock
PMGM
| $1.94M | 0.69% |
200,000
| – | – |
2021 Q1
1 quarter
|
|
|
TRIL
42
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.93M | 0.68% |
198,699
| – | – |
2020 Q1
5 quarters
|
|
|
KAIRW
43
DELISTED
Kairos Acquisition Corp. Warrant
KAIRW
| $1.69M | 0.6% |
146,528
+15,841
| +12% | +$11.7K |
2021 Q1
1 quarter
|
|
|
ASLN
44
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $1.58M | 0.56% |
11,955
+1,020
| +9% | +$128K |
2021 Q1
1 quarter
|
|
45
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.46M | 0.52% |
81,166
+20,900
| +35% | +$336K |
2020 Q4
2 quarters
|
|
46
uniQure
QURE
$1.51B
| $1.44M | 0.51% |
46,766
+5,000
| +12% | +$168K |
2019 Q4
6 quarters
|
|
47
Coherus Oncology
CHRS
$153M
| $1.38M | 0.49% |
99,655
| – | – |
2017 Q2
16 quarters
|
|
|
QUOT
48
DELISTED
Quotient Technology Inc
QUOT
| $1.35M | 0.48% |
125,000
+75,000
| +150% | +$1M |
2020 Q4
2 quarters
|
|
49
Inspired Entertainment
INSE
$86.2M
| $1.27M | 0.45% |
+100,000
| New | +$1.01M |
2021 Q2
0 quarters
|
|
50
Viking Therapeutics
VKTX
$3.2B
| $1.25M | 0.44% |
208,102
| – | – |
2017 Q4
14 quarters
|
|
Similar funds
FA
KCP
HCIA
ISG
TPCM
DCM
MCL
DVC
David M. Knott's Q2 2021 Portfolio in Review
As of Q2 2021, David M. Knott held 164 positions worth $281M, up 20% from $234M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
David M. Knott deployed $23.4M of net new capital in Q2 2021, opening 35 new positions and adding to 26 existing holdings. Its largest new stake was Coliseum Acquisition Corp. Unit: 1,485,000 shares worth $14.7M.
By sector, the portfolio is most concentrated in Financials at 28% of assets, up from 23% a quarter earlier, followed by Healthcare and Miscellaneous.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2.37M trimmed.
- David M. Knott's largest Q2 2021 buy was Coliseum Acquisition Corp. Unit: 1,485,000 shares worth $14.7M.
- David M. Knott added most to Calumet Specialty Products in Q2 2021, an estimated $1.9M increase.
- David M. Knott's biggest Q2 2021 reduction was Gilead Sciences, cutting an estimated $2.37M.
- David M. Knott fully exited African Gold Acquisition Corp Units in Q2 2021, selling an estimated $6.11M.
- David M. Knott's ten largest holdings make up 46% of its $281M portfolio in Q2 2021.
- David M. Knott opened 35 new positions and closed 17 in Q2 2021.
- David M. Knott's portfolio value rose 20% quarter-over-quarter to $281M.
Based on David M. Knott's 13F filing for Q2 2021, filed 13 Aug 2021.